Development of cyclosporine A microemulsion for parenteral delivery

References

• Beauchesne PR, Chung NSC, Wasan KM. Cyclosporine A: A review of current oral and intravenous delivery systems. Drug Dev Ind Pharm, 2007;33(3):211–20
   PubMed Web of Science ®Google Scholar
• Cordes N, Plasswilm L. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol (R)): Role of the solvent cremophor EL/ethanol. Anticancer Res, 1998;18(3A):1851–7
   PubMed Web of Science ®Google Scholar
• Corporation NP, Inventor. 2005. Sandimmune soft gelatin capsules, oral solution and injection
   Google Scholar
• Darole PS, Hegde DD, Nair HA. Formulation and evaluation of microemulsion based delivery system for amphotericin B. AAPS PharmSciTech, 2008;9(1):122–8
   PubMed Web of Science ®Google Scholar
• Date AA, Nagarsenker MS. Design and evaluation of microemulsions for improved parenteral delivery of propofol. AAPS PharmSciTech, 2008a;9(1):138–45
   PubMed Web of Science ®Google Scholar
• Date AA, Nagarsenker MS. Parenteral microemulsions: An overview. Int J Pharm, 2008b;355(1–2):19–30
   PubMed Web of Science ®Google Scholar
• Djordjevic L, Primorac M, Stupar M, Krajisnik D. Characterization of caprylocaproyl macrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. Int J Pharm, 2004;271(1–2):11–19
   PubMed Web of Science ®Google Scholar
• Ehinger KH, Hansson MJ, Sjovall F, Elmer E. Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor (R) EL. Clin Drug Investig, 2013;33(1):25–34
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer, 2001;37(13):1590–8
   PubMed Web of Science ®Google Scholar
• Hirunpanich V, Sato H. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. Eur J Pharm Biopharm, 2009;73(2):247–52
   PubMed Web of Science ®Google Scholar
• Ismailos G, Reppas C, Dressman JB, Macheras P. Unusual solubility behavior of Cyclosporine-A in aqueous-media. J Pharm Pharmacol, 1991;43(4):287–9
   PubMed Web of Science ®Google Scholar
• Jain J, Fernandes C, Patravale V. Formulation development of parenteral phospholipid-based microemulsion of etoposide. AAPS PharmSciTech, 2010;11(2):826–31
   PubMed Web of Science ®Google Scholar
• Kawakami K, Yoshikawa T, Moroto Y, Kanaoka E, Takahashi K, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs – I. Prescription design. J Control Release, 2002;81(1–2):65–74
   PubMed Web of Science ®Google Scholar
• Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev, 2002;54(Suppl 1):S77–98
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 2000;45(1):89–121
   PubMed Web of Science ®Google Scholar
• Li X, Yue Y, Zhou Y, Fan Y, Fan C, Huang Y, Wu F, Liu Y. An oil-free microemulsion for intravenous delivery of diallyl trisulfide: Formulation and evaluation. Int J Pharm, 2011;407(1–2):158–66
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Y, Li S. Advanced delivery of ciclosporin A: Present state and perspective. Expert Opin Drug Deliv, 2007;4(4):349–58
   PubMed Web of Science ®Google Scholar
• Radomska A, Dobrucki R. The use of some ingredients for microemulsion preparation containing retinol and its esters. Int J Pharm, 2000;196(2):131–4
   PubMed Web of Science ®Google Scholar
• Rahman Z, Xu X, Katragadda U, Krishnaiah YS, Yu L, Khan MA. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion. Mol Pharm, 2014;11:787–99
   PubMed Web of Science ®Google Scholar
• Sane R, Mittapalli RK, Elmquist WF. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci, 2013;102(4):1343–54
   PubMed Web of Science ®Google Scholar
• Shen Dai YK. 2000. Hong Kong drug approval and practical guide, 1st edn. Beijing: Chinese Medical Science and Technology Press, pp. 220–7
   Google Scholar
• Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res, 2004;21(2):201–30
   PubMed Web of Science ®Google Scholar
• Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med, 1994;331(6):365–76
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet, 2005;44(3):247–61
   PubMed Web of Science ®Google Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles – Implications for cancer chemotherapy. Clin Pharmacokinet, 2003;42(7):665–85
   PubMed Web of Science ®Google Scholar
• Ustundag-Okur N, Gokce EH, Egrilmez S, Ozer O, Ertan G. Novel ofloxacin-loaded microemulsion formulations for ocular delivery. J Ocul Pharmacol Ther, 2014;30:319–32
   PubMed Web of Science ®Google Scholar
• Warisnoicharoen W, Lansley AB, Lawrence MJ. Nonionic oil-in-water microemulsions: The effect of oil type on phase behaviour. Int J Pharm, 2000;198(1):7–27
   PubMed Web of Science ®Google Scholar
• Yuan Y, Li SM, Mo FK, Zhong DF. Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm, 2006;321(1–2):117–23
   PubMed Web of Science ®Google Scholar
• Yuan Y, Li SM, Yu LM, Deng P, Zhong DF. Physicochemical properties and evaluation of microemulsion systems for transdermal delivery of meloxicam. Chem Res Chin Univ, 2007;23(1):81–6
   Web of Science ®Google Scholar
• Zaghloul AA, Hussain A, Khan MA, Ahsan F. Development of a HPLC method for the determination of cyclosporin-A in rat blood and plasma using naproxen as an internal standard. J Pharm Biomed Anal, 2003;31(6):1101–7
   PubMed Web of Science ®Google Scholar
• Zhao XL, Chen DW, Gao P, Ding PT, Li KX. Synthesis of ibuprofen eugenol ester and its microemulsion formulation for parenteral delivery. Chem Pharm Bull, 2005;53(10):1246–50
   PubMed Web of Science ®Google Scholar